Comparing MRI techniques for diagnosing optic neuritis in multiple sclerosis
Comparison of Diagnostic Performances of 3D FLAIR, DIR and PSIR Sequences in Optic Neuritis
This study is testing which MRI technique works best to spot optic neuritis in people with multiple sclerosis and related conditions.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Strasbourg, France Academic / other |
| Locations | 1 site (Strasbourg, Les Hôpitaux Universitaires de Strasbourg) |
| Trial ID | NCT06494228 on ClinicalTrials.gov |
What this trial studies
This observational study aims to improve the diagnostic performance of MRI sequences in detecting optic neuritis among patients with multiple sclerosis and NMO spectrum diseases. It compares the effectiveness of three MRI sequences: 3D FLAIR, DIR, and PSIR, to determine which provides the best sensitivity for identifying optic neuritis. Previous studies have suggested that PSIR and DIR sequences may outperform FLAIR in detecting demyelinating lesions, but limited research has focused specifically on optic neuritis. The study will analyze MRI data collected from patients who have undergone these imaging techniques.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older diagnosed with multiple sclerosis or NMO spectrum diseases who have undergone MRI with the specified sequences.
Not a fit: Patients who do not have multiple sclerosis or NMO spectrum diseases, or those who have not undergone the required MRI sequences, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate diagnoses of optic neuritis, improving patient care for those with multiple sclerosis.
How similar studies have performed: Previous studies have shown promising results with similar MRI techniques, indicating potential for improved diagnostic capabilities.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Major subject (≥18 years old) * Subject suffering from multiple sclerosis or an NMO spectrum disease * Subject having received an MRI including 3D FLAIR, 3D DIR and 3D PSIR sequences * Brain MRIs of eligible subjects acquired between April 1, 2019 and November 30, 2021. * No opposition to the reuse of its data for scientific research purposes. Exclusion Criteria: * Presence of opposition from the subject (and/or their legal representative if applicable) to the reuse of their data for scientific research purposes. * Artifacts not allowing satisfactory interpretation
Where this trial is running
Strasbourg, Les Hôpitaux Universitaires de Strasbourg
- Service de Radiologie II, CHU de Strasbourg — Strasbourg, Les Hôpitaux Universitaires de Strasbourg, France (Recruiting)
Study contacts
- Study coordinator: François-Daniel ARDELLIER, MD
- Email: francois-daniel.ardellier@chru-strasbourg.fr
- Phone: 33 3 68 76 53 37
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.